References of "Beckers, Albert"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailHypercalcémie réfractaire et sécrétion ectopique de calcitonine dans un cancer neuroendocrine du pancréas : Effets hypocalcémiants du Cinacalcet
VALDES SOCIN, Hernan Gonzalo ULg; LOLY, Jean-Philippe ULg; BETEA, Daniela ULg et al

in Annales d'Endocrinologie (2013, September), 74(4), 235-462

Introduction: Paraneoplastic hypercalcemia is a sign of poor prognosis, as it is particularly resistant to the usual hypocalcemic treatments. Observation: In 2009, a well differentiated pancreatic ... [more ▼]

Introduction: Paraneoplastic hypercalcemia is a sign of poor prognosis, as it is particularly resistant to the usual hypocalcemic treatments. Observation: In 2009, a well differentiated pancreatic neuroendocrine tumor (Ki-67= 2%) is diagnosed in a 52-year-old diabetic man. The tumor is revealed with a splenic and hepatic carcinomatosis. Plasmatic calcium was: 3.54 mmol/L (2.15 - 2.6). Biology showed hypophosphatemia, PTH < 4 ng/ml, high 1-25 OH VitD, calcitonin: 1016 ng/ml (< 12 ng/ml). He had hypercalciuria and hypophosphaturia. He received for two years several cycles of Streptozotocin-ADRIAMYCIN and FOLFOX, with partial control of the tumor mass and calcium levels. In 2012, calcitonin levels are 29 ng/ml whereas calcemia is 3.17 mmol/L. Hypercalcemia is refractory to hyperhydration, diuretics, corticosteroids, and bisphosphonates therapy. Cinacalcet (Mimpara) is prescribed up to 120 mg/day (PO). Calcemia decreases gradually from 3 to 2.87 and then 2.76 mmol/L. PTH and calcitonin-the tumor mass remain unchanged. After two months of Cinacalcet treatment, Sunitinib (Sutent) 37.5 mg per day was added. During the third month, calcium levels dropped to 2.09 mmol/L and PTH raised to 78 pg/ml, requiring discontinuation of Mimpara. Calcitonin normalized, with a further improvement over pancreatic and metastatic lesions. Conclusion: Cinacalcet is a Calcium Sensing Receptor oral agonist. Cinacalcet hypocalcemic effects have not been previously documented in pancreatic paraneoplastic hypercalcemia. In our patient, Cinacalcet has significantly improved cancer prognosis: this drug could be a new alternative in paraneoplastic hypercalcemia. [less ▲]

Detailed reference viewed: 77 (5 ULg)
Full Text
Peer Reviewed
See detailMeans, Motive, and Opportunity: SDH Mutations Are Suspects in Pituitary Tumors.
BECKERS, Albert ULg

in Journal of Clinical Endocrinology and Metabolism (2013), 98(6), 2274-6

Detailed reference viewed: 36 (18 ULg)
Full Text
See detailCharacteristics of patients with pituitary gigantism : results of an international study
Rostomyan, Liliya ULg; Daly, Adrian ULg; Tichomirowa, M et al

in Endocrine abstracts - 15th European Congress of Endocrinology (2013, May)

Detailed reference viewed: 29 (4 ULg)
Full Text
See detailLessons from the Liege Acromegaly Survey (LAS)
PETROSSIANS, Patrick ULg; Zacharieva, Sabina; Chanson, Philippe et al

in Endocrine Abstracts - 15 the European Congress of Endocrinology (2013, May)

Detailed reference viewed: 30 (4 ULg)
Full Text
See detailReceptor expression in craniopharyngiomas causing tumor growth in pregnancy : case report and review of the literature
Tome, Monica; VROONEN, Laurent ULg; THIRY, Albert ULg et al

in Endocrine Abstracts - 15th European Congress of Endocrinology (2013, May)

Detailed reference viewed: 24 (8 ULg)
Full Text
See detailA national survey on the prevalence and treatment outcome of active Cushing's disease in Belgium
Bex, M; Nauwelaerts, H; T'Sjoen, Guy et al

in Endocrine Abstracts - 15th European Congress of Endocrinology (2013, May)

Detailed reference viewed: 15 (2 ULg)
See detailAdenomas Pituitarios Familiares Aislados (FIPA)
Beckers, Albert ULg

Scientific conference (2013, April)

Detailed reference viewed: 18 (2 ULg)
See detailHistoria de la Acromegalia y del Gigantismo
Beckers, Albert ULg

Scientific conference (2013, April)

Detailed reference viewed: 41 (2 ULg)
See detailEpidemiology and genetics of pituitary tumors
Beckers, Albert ULg

Scientific conference (2013, February)

Detailed reference viewed: 17 (3 ULg)
Full Text
Peer Reviewed
See detailFamilial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene.
BECKERS, Albert ULg; Aaltonen, Lauri A.; Daly, Adrian ULg et al

in Endocrine Reviews (2013)

Pituitary adenomas are one of the most frequent intracranial tumors and occur with a prevalence of approximately 1:1000 in the developed world. Pituitary adenomas have a serious disease burden, and their ... [more ▼]

Pituitary adenomas are one of the most frequent intracranial tumors and occur with a prevalence of approximately 1:1000 in the developed world. Pituitary adenomas have a serious disease burden, and their management involves neurosurgery, biological therapies, and radiotherapy. Early diagnosis of pituitary tumors while they are smaller may help increase cure rates. Few genetic predictors of pituitary adenoma development exist. Recent years have seen two separate, complimentary advances in inherited pituitary tumor research. The clinical condition of familial isolated pituitary adenomas (FIPA) has been described, which encompasses the familial occurrence of isolated pituitary adenomas outside of the setting of syndromic conditions like multiple endocrine neoplasia type 1 and Carney complex. FIPA families comprise approximately 2% of pituitary adenomas and represent a clinical entity with homogeneous or heterogeneous pituitary adenoma types occurring within the same kindred. The aryl hydrocarbon receptor interacting protein (AIP) gene has been identified as causing a pituitary adenoma predisposition of variable penetrance that accounts for 20% of FIPA families. Germline AIP mutations have been shown to associate with the occurrence of large pituitary adenomas that occur at a young age, predominantly in children/adolescents and young adults. AIP mutations are usually associated with somatotropinomas, but prolactinomas, nonfunctioning pituitary adenomas, Cushing disease, and other infrequent clinical adenoma types can also occur. Gigantism is a particular feature of AIP mutations and occurs in more than one third of affected somatotropinoma patients. Study of pituitary adenoma patients with AIP mutations has demonstrated that these cases raise clinical challenges to successful treatment. Extensive research on the biology of AIP and new advances in mouse Aip knockout models demonstrate multiple pathways by which AIP may contribute to tumorigenesis. This review assesses the current clinical and therapeutic characteristics of more than 200 FIPA families and addresses research findings among AIP mutation-bearing patients in different populations with pituitary adenomas. [less ▲]

Detailed reference viewed: 47 (24 ULg)
Full Text
Peer Reviewed
See detailHigher risk of death among MEN1 patients with mutations in the JunD interacting domain. A Groupe d'étude des Tumeurs Endocrines (GTE) cohort study
Thevenon, Julien; Bourredjem, Abderrahmane; Faivre, Laurence et al

in Human Molecular Genetics (2013)

BackgroundMultiple Endocrine Neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors ... [more ▼]

BackgroundMultiple Endocrine Neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors. Although genotype-phenotype studies have so far failed to identify any statistical correlations, some families harbor recurrent tumor patterns. The function of MENIN is unclear but has been described through the discovery of its interacting partners. Mutations in the interacting domains of MENIN functional partners have been shown to directly alter its regulation abilities.MethodsWe report on a cohort of MEN1 patients from the Groupe d'etude des Tumeurs Endocrines. Patients with a molecular diagnosis and a clinical follow-up, totalling 262 families and 806 patients were included. Associations between mutation type, location or interacting factors of the MENIN protein and death as well as the occurrence of MEN1-related tumors were tested using a frailty Cox model to adjust for potential heterogeneity across families.ResultsAccounting for the heterogeneity across families, the overall risk of death was significantly higher when mutations affected the JunD interacting domain (adjusted HR=1.88: 95%-CI=1.15- 3.07). Patients had a higher risk of death from cancers of the MEN1 spectrum (HR=2.34; 95%-CI=1.23- 4.43).ConclusionThis genotype-phenotype correlation study confirmed the lack of direct genotype-phenotype correlations. However, patients with mutations affecting the JunD interacting domain had a higher risk of death secondary to a MEN1 tumor and should thus be considered for surgical indications, genetic counseling and follow-up. [less ▲]

Detailed reference viewed: 31 (12 ULg)
Full Text
Peer Reviewed
See detailPrise en charge des prolactinomes
VROONEN, Laurent ULg; Daly, Adrian ULg; Beckers, Albert ULg

in Revue Médicale Suisse (2013), 9

Detailed reference viewed: 12 (7 ULg)
Full Text
See detailThe clinical characteristics of pituitary adenomas (PA) in patients with primary hyperparathyroidism (PHPT) with and without MEN1 mutation
Filipponi, S; Rostomyan, Liliya ULg; VALDES SOCIN, Hernan Gonzalo ULg et al

in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013)

Detailed reference viewed: 9 (4 ULg)
Full Text
See detailThe clinical and genetic characteristics of patients with gigantism
Rostomyan, Liliya ULg; Daly, Adrian ULg; Tichomirowa, M et al

in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013)

Detailed reference viewed: 46 (5 ULg)
Full Text
Peer Reviewed
See detailSomatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations
Jaffrain-Réa, ML; Rotondi, S; Turchi, A et al

in Endocrine-Related Cancer (2013), 20

Detailed reference viewed: 33 (10 ULg)
Full Text
Peer Reviewed
See detail2013 European Thyroid Association guidelines for the diagnosis and treatment of TSH-secreting pituitary tumors
Beck-Peccoz, P; Lania, A; Beckers, Albert ULg et al

in European Thyroïd Journal (2013)

Detailed reference viewed: 34 (10 ULg)
Full Text
Peer Reviewed
See detaille syndrome auto-immun thyrogastrique: ses effets sur les micronutriments et la tumorigénèse gastrique.
VALDES SOCIN, Hernan Gonzalo ULg; LUTTERI, Laurence ULg; CAVALIER, Etienne ULg et al

in Revue Médicale de Liège (2013)

Summary : The thyrogastric autoimmune syndrome (TAS) was described in patients in whom the serum cross-reacted both with gastric parietal cells antigens and thyroid antigens. We report two cases ... [more ▼]

Summary : The thyrogastric autoimmune syndrome (TAS) was described in patients in whom the serum cross-reacted both with gastric parietal cells antigens and thyroid antigens. We report two cases illustrating the spectrum of pathogical features of TAS. The first case associates Hashimoto’s thyroiditis and anemia perniciosa,and develops a gastric neuroendocrine tumor during follow up. The second case presents with a Graves’ disease and an autoimmune reversible gastritis, secondary to Helicobacter Pylori. Whereas type III autoimmune polyendocrinopathy is rare, TAS is frequent in our experience. Some 13% (32/240) of patients that we have prospectively followed affected with thyroiditis have also autoimmune gastritis. Helicobacter pylori is clearly implicated in 16% of autoimmune gastritis cases. Infection, malabsorption and gastritis are potentially reversible after bacterial eradication treatment. In the other 84% of gastritis patients, no histological or serological proof of Helicobacter pylori is found. Gastric autoimmunity is then irreversible, leading to gastric severe atrophy, hypochlorhydria and hypergastrinemia. Hypergastrinemia stimulates enterochromaffin cell hyperplasia, possibly progressing c to neuroendocrine tumors. We propose a diagnostic approach to improve the characterization of TAS. We review the literature on the subject and discuss some interesting animal models of infectious gastric autoimmunity [less ▲]

Detailed reference viewed: 46 (11 ULg)
Full Text
See detailFamilial Pituitary Adenomas : An overview
Vasilev, V; Daly, Adrian ULg; Beckers, Albert ULg

in Hayat, MA (Ed.) Tumors of the Central nervous system (2013)

Detailed reference viewed: 50 (18 ULg)
Full Text
See detailThe Role of Aryl Hydrocarbon Receptor (AHR) and AHR-Interacting Protein (AIP) in the Pathogenesis of Pituitary Adenomas
Jaffrain Rea, ML; Beckers, Albert ULg

in Hayat, MA (Ed.) Tumors of the Central nervous system (2013)

Detailed reference viewed: 21 (9 ULg)